Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments

AAPS Journal

Volumn 20, Issue 1, 2018, Pages

  Lauschke, Volker M ^a   Milani, Lili ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

clinical implementation; cytochrome P450; oncology; pharmacogenetics; precision medicine

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZATHIOPRINE; BIOLOGICAL MARKER; CAPECITABINE; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; DICLOFENAC; DRUG METABOLIZING ENZYME; EFAVIRENZ; FLUCLOXACILLIN; FLUOROURACIL; IRINOTECAN; ISONIAZID; LUMIRACOXIB; MERCAPTOPURINE; METOCLOPRAMIDE; NEVIRAPINE; PERHEXILINE; PHENYTOIN; PROTON PUMP INHIBITOR; SIMVASTATIN; TEGAFUR; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ABCB1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALK GENE; ALLELE; ANALGESIC ACTIVITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL PRACTICE; CYP GENE; CYP28 GENE; CYP2A6 GENE; CYP2B6 GENE; CYP2C19 GENE; CYP2C8 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; CYP4F2 GENE; CYP6 GENE; CYP6BQ23 GENE; CYP6CY3 GENE; CYP6G1 GENE; CYP9Q1 GENE; CYP9Q2 GENE; CYP9Q3 GENE; DIARRHEA; DPYD GENE; DRESS SYNDROME; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EGFR GENE; ERBB2 GENE; EUROPEAN MEDICINES AGENCY; FGFR GENE; FOOD AND DRUG ADMINISTRATION; G6PD GENE; GENE; GENE LOCUS; GENETIC VARIABILITY; GENOME; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GERMLINE GENOME; GSTM1 GENE; HEREDITY; HLA B GENE; HLA GENE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; JAK2 GENE; KIT GENE; LOSS OF FUNCTION MUTATION; MYOPATHY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NEXT GENERATION SEQUENCING; NONHUMAN; ONCOGENE; ONCOLOGY; PDGFRA GENE; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETIC VARIANT; PHARMACOGENOMICS; PRESCRIPTION; PUBLIC HEALTH; REVIEW; RHABDOMYOLYSIS; SLC19A1 GENE; SLC22A1 GENE; SLCO1B1 GENE; SOMATIC GENOME; SOMATIC MUTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TPMT GENE; TREATMENT INDICATION; UGT1A1 GENE; UGT2B15 GENE; UGT2B17 GENE; VKORC1 GENE; GENETIC POLYMORPHISM; GENETIC VARIATION; NEOPLASM; PATIENT SATISFACTION; PHARMACOGENETICS;

BIOMARKERS; GENETIC VARIATION; HUMANS; NEOPLASMS; ONCOGENES; PATIENT SATISFACTION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRECISION MEDICINE;

EID: 85037059976     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-017-0161-x     Document Type: Review

References (136)

1. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals—a review of the recent literature. Drug Saf. 2007;30(5):379–407. https://doi.org/10.2165/00002018-200730050-00003.
2. Tache SV, Soennichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–89. https://doi.org/10.1345/aph.1P627.
3. Lauschke VM, Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17(10):1714. https://doi.org/10.3390/ijms17101714.
4. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13(1):1–11. https://doi.org/10.1038/tpj.2012.45.
5. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4(10):825–33. https://doi.org/10.1038/nrd1851.
6. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–91. https://doi.org/10.1126/science.286.5439.487.
7. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;17(4 Pt 2):E1714–3. https://doi.org/10.1002/cpt.690.
8. Warton K, Mahon KL, Samimi G. Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer. 2016;23(3):R157–R71. https://doi.org/10.1530/ERC-15-0369.
9. Lauschke VM, Ivanov M, Ingelman-Sundberg M. Pitfalls and opportunities for epigenomic analyses focused on disease diagnosis, prognosis, and therapy. Trends Pharmacol Sci. 2017;38(9):765–70. https://doi.org/10.1016/j.tips.2017.05.007.
10. Lauschke VM, Barragan I, Ingelman-Sundberg M. Pharmacoepigenetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities. Ann Rev Pharmacol Toxicol. 2017.
11. Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7(6):1003–15. https://doi.org/10.2217/epi.15.56.
12. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20(8):342–9. https://doi.org/10.1016/S0165-6147(99)01363-2.
13. Danielson PB, MacIntyre RJ, Fogleman JC. Molecular cloning of a family of xenobiotic-inducible drosophilid cytochrome p450s: evidence for involvement in host-plant allelochemical resistance. Proc Natl Acad Sci. 1997;94(20):10797–802. https://doi.org/10.1073/pnas.94.20.10797.
14. Daborn PJ, Yen JL, Bogwitz MR, Le Goff G, Feil E, Jeffers S, et al. A single p450 allele associated with insecticide resistance in Drosophila. Science. 2002;297(5590):2253–6. https://doi.org/10.1126/science.1074170.
15. Karatolos N, Williamson MS, Denholm I, Gorman K, Ffrench-Constant RH, Bass C. Over-expression of a cytochrome P450 is associated with resistance to pyriproxyfen in the greenhouse whitefly Trialeurodes vaporariorum. PLoS One. 2012;7(2):e31077–8. https://doi.org/10.1371/journal.pone.0031077.
16. Mao W, Schuler MA, Berenbaum MR. CYP9Q-mediated detoxification of acaricides in the honey bee (Apis mellifera). Proc Natl Acad Sci U S A. 2011;108(31):12657–62. https://doi.org/10.1073/pnas.1109535108.
17. Zimmer CT, Bass C, Williamson MS, Kaussmann M, Wölfel K, Gutbrod O, et al. Molecular and functional characterization of CYP6BQ23, a cytochrome P450 conferring resistance to pyrethroids in European populations of pollen beetle, Meligethes aeneus. Insect Biochem Mol Biol. 2014;45(C):18–29. https://doi.org/10.1016/j.ibmb.2013.11.008.
18. Bass C, Zimmer CT, Riveron JM, Wilding CS, Wondji CS, Kaussmann M, et al. Gene amplification and microsatellite polymorphism underlie a recent insect host shift. Proc Natl Acad Sci U S A. 2013;110(48):19460–5. https://doi.org/10.1073/pnas.1314122110.
19. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13. https://doi.org/10.1038/sj.tpj.6500285.
20. Meletis J, Konstantopoulos K. Favism—from the ‘avoid fava beans’ of Pythagoras to the present. HAEMA. 2004;7(1):17–21.
21. Carr DF, la Porte CJL, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010;65(9):1889–93. https://doi.org/10.1093/jac/dkq260.
22. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis J. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics. 2005;15(3):151–8. https://doi.org/10.1097/01213011-200503000-00003.
23. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J, et al. Clinical response and side effects of metoclopramide associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46(6):494–503. https://doi.org/10.1097/MCG.0b013e3182522624.
24. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with Perhexiline liver-injury. Gut. 1984;25(10):1057–64. https://doi.org/10.1136/gut.25.10.1057.
25. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12). doi: https://doi.org/10.1093/jnci/dju298.
26. Huang Y-S, Su W-J, Huang Y-H, Chen C-Y, Chang F-Y, Lin H-C, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007;47(1):128–34. https://doi.org/10.1016/j.jhep.2007.02.009.
27. Leiro V, Fernández-Villar A, Valverde D, Constenla L, Vázquez R, Piñeiro L, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 2008;28(6):835–9. https://doi.org/10.1111/j.1478-3231.2008.01700.x.
28. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382–8. https://doi.org/10.1200/JCO.2004.07.173.
29. Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272–81. https://doi.org/10.1053/j.gastro.2006.11.023.
30. Nguyen CM, Mendes MAS, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Currents. 2011;3:RRN1236–7. https://doi.org/10.1371/currents.RRN1236.
31. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–99. https://doi.org/10.1056/NEJMoa0801936.
32. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9. https://doi.org/10.1038/ng.379.
33. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2007;8(3):186–95. https://doi.org/10.1038/sj.tpj.6500458.
34. Hautekeete ML, Horsmans Y, van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117(5):1181–6. https://doi.org/10.1016/S0016-5085(99)70404-X.
35. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study. Pharmacogenomics J. 2007;8(1):29–33. https://doi.org/10.1038/sj.tpj.6500442.
36. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–4. https://doi.org/10.1038/ng.632.
37. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32. https://doi.org/10.1016/S0140-6736(02)07873-X.
38. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41. https://doi.org/10.1093/hmg/ddq537.
39. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91. https://doi.org/10.1111/j.1528-1167.2008.01719.x.
40. Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. 2005;102(11):4134–9. https://doi.org/10.1073/pnas.0409500102.
41. Cornejo Castro EM, Carr DF, Jorgensen AL, Alfirevic A, Pirmohamed M. HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. Pharmacogenet Genomics. 2015;25(4):186–98. https://doi.org/10.1097/FPC.0000000000000124.
42. Carr DF, Chaponda M, Jorgensen AL, Castro EC, van Oosterhout JJ, Khoo SH, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56(9):1330–9. https://doi.org/10.1093/cid/cit021.
43. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433–9. https://doi.org/10.1371/journal.pgen.1000433.
44. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57. https://doi.org/10.1001/jama.2009.1232.
45. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69(3):158–68. https://doi.org/10.1067/mcp.2001.113959.
46. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5(2):257–64. https://doi.org/10.1161/CIRCGENETICS.111.961144.
47. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2014;16(1):45–56. https://doi.org/10.1038/nrg3849.
48. Carter SC, McKone EF. Pharmacogenetics of cystic fibrosis treatment. Pharmacogenomics. 2016;17(13):1453–63. https://doi.org/10.2217/pgs.16.25.
49. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53. https://doi.org/10.1056/NEJMra1010600.
50. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014;15(1):349–70. https://doi.org/10.1146/annurev-genom-090413-025419.
51. Hertz DL, Rae J. Pharmacogenetics of cancer drugs. Annu Rev Med. 2015;66(1):65–81. https://doi.org/10.1146/annurev-med-053013-053944.
52. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012;129(5):e1343–7. https://doi.org/10.1542/peds.2011-2538.
53. Baugh RF, Archer SM, Mitchell RB, Rosenfeld RM, Amin R, Burns JJ, et al. Clinical practice guideline: tonsillectomy in children. 2011. p. S1–30.
54. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–9. https://doi.org/10.1016/S0140-6736(98)04474-2.
55. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–8. https://doi.org/10.1001/jama.287.13.1690.
56. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz H-J, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–41. https://doi.org/10.1038/nature02214.
57. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285–93. https://doi.org/10.1056/NEJMoa044503.
58. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012;125(16):1997–2005. https://doi.org/10.1161/CIRCULATIONAHA.111.070920.
59. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303. https://doi.org/10.1056/NEJMoa1311386.
60. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93. https://doi.org/10.1056/NEJMoa1310669.
61. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603–14. https://doi.org/10.1016/s0149-2918(01)80132-6.
62. Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79. https://doi.org/10.1056/NEJMoa0706135.
63. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554–8. https://doi.org/10.1038/nature11147.
64. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822–32. https://doi.org/10.1016/j.immuni.2008.04.020.
65. Swen JJ, Nijenhuis M, de Boer A, Grandia L, der Zee AHM-V, Mulder H, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2009;89(5):662–73. https://doi.org/10.1038/clpt.2011.34.
66. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499–500. https://doi.org/10.1038/clpt.2014.38.
67. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. JNCI J Natl Cancer Inst. 1999;91(23):2001–8. https://doi.org/10.1093/jnci/91.23.2001.
68. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia. 2009;23(5):971–4. https://doi.org/10.1038/leu.2008.317.
69. Colletti RB, Baldassano RN, Milov DE, Margolis PA, Bousvaros A, Crandall WV, et al. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2009;49(3):297–303. https://doi.org/10.1097/MPG.0b013e3181919695.
70. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007;32(2):187–95. https://doi.org/10.1111/j.1365-2710.2007.00805.x.
71. Compagni A, Bartoli S, Buehrlen B, Fattore G, Ibarreta D, de Mesa EG. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care. 2008;24(3):294–302. https://doi.org/10.1017/S0266462308080392.
72. Plumpton CO, Roberts D, Pirmohamed M, Hughes DA. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. PharmacoEconomics. 2016;34(8):771–93. https://doi.org/10.1007/s40273-016-0397-9.
73. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury; https://www.fda.gov/Drugs/DrugSafety/ucm256581.htm [Accessed 29.06.2017].
74. Wilson PM, Danenberg PV, Johnston PG, Lenz H-J, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11(5):282–98. https://doi.org/10.1038/nrclinonc.2014.51.
75. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099–105. https://doi.org/10.1200/JCO.2007.13.3934.
76. Diasio RB, Harris BE. Clinical-pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215–37. https://doi.org/10.2165/00003088-198916040-00002.
77. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD* 2Ato individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227–34. https://doi.org/10.1200/JCO.2015.63.1325.
78. Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, et al. Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther. 2015;98(6):611–21. https://doi.org/10.1002/cpt.258.
79. Matthaei J, Tzvetkov MV, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg JB, et al. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med. 2016;1–12. doi: https://doi.org/10.1186/s13073-016-0372-2.
80. Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet Genomics. 2015;25(12):584–94. https://doi.org/10.1097/FPC.0000000000000172.
81. Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–9. https://doi.org/10.1038/gim.2016.33.
82. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65. https://doi.org/10.1038/nature11632.
83. Tennessen JA, Bigham AW, O’Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64–9. https://doi.org/10.1126/science.1219240.
84. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. https://doi.org/10.1038/nature19057.
85. 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. https://doi.org/10.1038/nature15393.
86. Apellaniz-Ruiz M, Inglada-Pérez L, Naranjo MEG, Sánchez L, Mancikova V, Currás-Freixes M, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015;15(3):288–92. https://doi.org/10.1038/tpj.2014.67.
87. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G?T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2007;64(4):357–65. https://doi.org/10.1007/s00228-007-0412-3.
88. Roederer MW, McLeod HL. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics. 2010;11(5):633–6. https://doi.org/10.2217/pgs.10.55.
89. Roederer MW, Sanchez-Giron F, Kalideen K, Kudzi W, McLeod HL, Zhang W. Pharmacogenetics and rational drug use around the world. Pharmacogenomics. 2011;12(6):897–905. https://doi.org/10.2217/pgs.11.17.
90. Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends Pharmacol Sci. 2016;37(2):85–6. https://doi.org/10.1016/j.tips.2015.10.006.
91. Peterson TA, Doughty E, Kann MG. Towards precision medicine: advances in computational approaches for the analysis of human variants. J Mol Biol. 2013;425(21):4047–63. https://doi.org/10.1016/j.jmb.2013.08.008.
92. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(8):1073–81. https://doi.org/10.1038/nprot.2009.86.
93. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. https://doi.org/10.1038/nmeth0410-248.
94. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688–13. https://doi.org/10.1371/journal.pone.0046688.
95. Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31(5):761–3. https://doi.org/10.1093/bioinformatics/btu703.
96. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1545–602. https://doi.org/10.1016/S0140-6736(16)31678-6.
97. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–31. https://doi.org/10.1126/science.1196333.
98. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44(7):760–4. https://doi.org/10.1038/ng.2291.
99. Kleer CG, Cao Q, Varambally S, Shen RL, Ota L, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci. 2003;100(20):11606–11. https://doi.org/10.1073/pnas.1933744100.
100. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010;107(49):20980–5. https://doi.org/10.1073/pnas.1012525107.
101. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57(15):3126–30.
102. Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108(9):3761–6. https://doi.org/10.1073/pnas.1014835108.
103. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–8. https://doi.org/10.1038/nature10860.
104. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318–32. https://doi.org/10.1038/nrc.2017.8.
105. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFRMutations. J Clin Oncol. 2013;31(27):3327–34. https://doi.org/10.1200/JCO.2012.44.2806.
106. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.
107. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. https://doi.org/10.1056/NEJMoa0909530.
108. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603–9. https://doi.org/10.1200/JCO.2008.18.0612.
109. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92. https://doi.org/10.1056/NEJMoa044238.
110. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40. https://doi.org/10.1056/NEJMoa1612674.
111. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457.
112. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18(8):1321–31. https://doi.org/10.1038/sj.leu.2403426.
113. An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR Jr, Chen Z-S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255–68. https://doi.org/10.1016/j.leukres.2010.04.016.
114. O’Hare T, Walters DK, Stoffregen EP, Jia TP, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500–5. https://doi.org/10.1158/0008-5472.CAN-05-0259.
115. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96. https://doi.org/10.1056/NEJMoa1306494.
116. Ding L, Wendl MC, McMichael JF, Raphael BJ. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet. 2014;15(8):556–70. https://doi.org/10.1038/nrg3767.
117. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014;11(7):432–8. https://doi.org/10.1038/nrclinonc.2014.54.
118. Tattini L, D Aurizio R, Magi A. Detection of genomic structural variants from next-generation sequencing data. Front Bioeng Biotechnol. 2015;3:1–8. https://doi.org/10.3389/fbioe.2015.00092.
119. Carneiro MO, Russ C, Ross MG, Gabriel SB, Nusbaum C, DePristo MA. Pacific biosciences sequencing technology for genotyping and variation discovery in human data. BMC Genomics. 2012;13(1):375. https://doi.org/10.1186/1471-2164-13-375.
120. Pendleton M, Sebra R, Pang AWC, Ummat A, Franzen O, Rausch T, et al. Assembly and diploid architecture of an individual human genome via single-molecule technologies. Nat Methods. 2015;12(8):780–6. https://doi.org/10.1038/nmeth.3454.
121. Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133–8. https://doi.org/10.1126/science.1162986.
122. Qiao W, Yang Y, Sebra R, Mendiratta G, Gaedigk A, Desnick RJ, et al. Long-read single molecule real-time full gene sequencing of cytochrome P450-2D6. Hum Mutat. 2016;37(3):315–23. https://doi.org/10.1002/humu.22936.
123. Buermans HPJ, Vossen RHAM, Anvar SY, Allard WG, Guchelaar H-J, White SJ, et al. Flexible and scalable full-length CYP2D6 long amplicon PacBio sequencing. Hum Mutat. 2017;38(3):310–6. https://doi.org/10.1002/humu.23166.
124. Wu TP, Wang T, Seetin MG, Lai Y, Zhu S, Lin K, et al. DNA methylation onN6-adenine in mammalian embryonic stem cells. Nature. 2016;532(7599):329–33. https://doi.org/10.1038/nature17640.
125. Clarke J, Wu H-C, Jayasinghe L, Patel A, Reid S, Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol. 2009;4(4):265–70. https://doi.org/10.1038/nnano.2009.12.
126. Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting DNA cytosine methylation using nanopore sequencing. Nat Methods. 2017;14(4):407–10. https://doi.org/10.1038/nmeth.4184.
127. Karamitros T, Magiorkinis G. A novel method for the multiplexed target enrichment of MinION next generation sequencing libraries using PCR-generated baits. Nucleic Acids Res. 2015;43(22):e152-e. https://doi.org/10.1093/nar/gkv773.
128. Dapprich J, Ferriola D, Mackiewicz K, Clark PM, Rappaport E, D’Arcy M, et al. The next generation of target capture technologies—large DNA fragment enrichment and sequencing determines regional genomic variation of high complexity. BMC Genomics. 2016;1–14. doi: https://doi.org/10.1186/s12864-016-2836-6.
129. Loose M, Malla S, Stout M. Real-time selective sequencing using nanopore technology. Nat Methods. 2016;13(9):751–4. https://doi.org/10.1038/nmeth.3930.
130. Adey A, Kitzman JO, Burton JN, Daza R, Kumar A, Christiansen L, et al. In vitro, long-range sequence information for de novo genome assembly via transposase contiguity. Genome Res. 2014;24(12):2041–9. https://doi.org/10.1101/gr.178319.114.
131. Bishara A, Liu Y, Weng Z, Kashef-Haghighi D, Newburger DE, West R, et al. Read clouds uncover variation in complex regions of the human genome. Genome Res. 2015;25(10):1570–80. https://doi.org/10.1101/gr.191189.115.
132. Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–10. https://doi.org/10.1038/tpj.2014.86.
133. Patrinos GP, Mitropoulou C. Measuring the value of pharmacogenomics evidence. Clin Pharmacol Ther. 2017;15(5):349–3. https://doi.org/10.1002/cpt.743.
134. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017;101(3):341–58. https://doi.org/10.1002/cpt.602.
135. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55(1):89–106. https://doi.org/10.1146/annurev-pharmtox-010814-124835.
136. Lauschke VM, Ingelman-Sundberg M. Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics. 2016;17(8):917–24. https://doi.org/10.2217/pgs-2016-0023.